Learning from Recent FDA Warning Letters: A Call for Proactive Compliance
Every FDA Warning Letter offers more than a glimpse into individual noncompliance; it reveals systemic risks that can impact the safety of clinical trial participants, the reliability of study data, and the integrity of an organization’s quality systems. Between 2024 and 2025, several Warning Letters were issued that highlight critical—and recurring—compliance failures in drug and […]
